

Attachment to

FORM PTO-1449 (Modified)	Attorney Docket No. 011823-002630	Serial No.: 08/484,537 <i>Page # 19</i>
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Queen	
	Filing Date: 6/7/95	Group: 1806

Reference Designation	U.S. PATENT DOCUMENTS
-----------------------	-----------------------

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
___ AA						
___ AB						
___ AC						
___ AD						
___ AE						
___ AF						
___ AG						
___ AH						
___ AI						
___ AJ						
___ AK						
___ AL						

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
<i>92</i> AN	EP 0456216	10/16/91	EP			
<i>92</i> AO	WO 96/05229	2/22/96	WIPO			
<i>92</i> AP	WO 92/11018	7/9/92	WIPO			
<i>92</i> AQ	EP 239400	8/3/94	EP			
<i>92</i> AR	WO 90/07861	7/26/90	WIPO			
<i>92</i> AS	WO 91/09966	7/11/91	WIPO			
<i>92</i> AT	WO 92/11383	7/9/92	WIPO			
<i>92</i> AU	WO 93/06231	4/1/93	WIPO			
<i>92</i> AV	WO 96/05229	2/22/96	WIPO			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
--

___ A1	Opposition to EP 0456216 by Medical Research Council including all documents supplied therewith <i>Incomplete Citation</i>
--------	--

Julie C. Rees, PLA

14 April 99

FORM PTO-1449 (Modified)		Attorney Docket No. 011823-002630	Serial No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen	
		Filing Date: 6/7/95	Group: 1806
— A2	Opposition to EP 0456216 by ICOS Corporation including all documents supplied therewith		
— A3	Opposition to EP 0456216 by CIBA-GEIGY AG including all documents supplied therewith		
— A4	Opposition to EP 0456216 by Celltech Therapeutics including all documents supplied therewith		
— A5	Opposition to EP 0456216 by Bayer AG including all documents supplied therewith		
— A6	Opposition to EP 0456216 by Chiron Corporation including all documents supplied therewith		
— A7	Opposition to EP 0456216 by SmithKline Beecham plc including all documents supplied therewith		
— A8	Opposition to EP 0456216 by Genentech, Inc. including all documents supplied therewith		
— A9	Opposition to EP 0456216 by IDEC Pharmaceuticals Corporation including all documents supplied therewith		
— A10	Opposition to EP 0456216 by Biotest Pharma GbmH including all documents supplied therewith		
— A11	Opposition to EP 0456216 by BIOTRANSPLANT, INC. including all documents supplied therewith		
— A12	Opposition to EP 0456216 by Bristol-Myers Squibb Company including all documents supplied therewith		
— A13	Opposition to EP 0456216 by Glaxo Group Limited including all documents supplied therewith		
— A14	Opposition to EP 0456216 by Boehringer Ingelheim GmbH including all documents supplied therewith		
— A15	Opposition to EP 0456216 by Merck Patent GmbH including all documents supplied therewith		
— A16	Opposition to EP 0456216 by Chugai Seiyaku Kabushiki Kaisha including all documents supplied therewith		
— A17	Opposition to EP 0456216 by Shering Corporation including all documents supplied therewith		
— A18	Opposition to EP 0456216 by Ixsys, Inc. including all documents supplied therewith		
— A19	Patentee's Observations on the Argument of the Opponents to EP 0456216, including Letter to the EPO, Observations, Exhibit I, "List of Documents Cited in the Proceedings", 0 and copies of D-88 to D-102		
— A20	Protest Under 37 CFR §1.291 submitted by Protein Design Labs, Inc. against Celltech's US application bound with ten attachments including Protein Design Labs Opposition to Celltech's EP 0460167		

Julie (Rever, P12)

14 Apr 99

FORM PTO-1449 (Modified)		Attorney Docket No. 011823-002630	Serial No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen	
		Filing Date: 6/7/95	Group: 1806
— A21	Kettleborough et al., "Humanization of a Mouse Monoclonal Antibody by CDR Grafting, the Importance of Framework Residues on Loop Formation", Protein Engineering, V. 4(7), pp. 773-783, 1991		
— A22	Chothia, et al., "Conformations of Immunoglobulin Hypervariable Regions", Nature V.342, pp. 877-883, 12/89		
— A23	Chothia, et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins", J. Mol. Biol. V. 196, pp. 901-917, 1987		
— A24	Co, et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen", PDL Labs, Journal of Immunology, V. 148, pp. 1149-1154, 2/15/92		
— A25	Caron, et al., "Biological and Immunological Features of Humanized M195 (Anti-CD33) Monoclonal Antibodies", Cancer Research, V. 52, pp. 6761-6767, 12/15/92		
— A26	Appendix I, Comparison of Humanized and Donor CAMPATH-1 Heavy Chains		
EXAMINER	<i>Julie C. Rees, PLS</i> DATE CONSIDERED <i>14 April 99</i>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attachment to Part 23

FORM PTO-1449 (Modified)	Attorney Docket No. 011823-002630	Serial No.: 08/484533
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Queen	
	Filing Date: 6/7/95	Group: 1806

JUL 28 1998

MATRIX CUSTOMER
SERVICE CENTER

Reference Designation

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
------------------	--------------	------	------	-------	-----------	------------------------------

GR-AA	5,530,101	6/25/96	Queen	—	—	
-------	-----------	---------	-------	---	---	--

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
AM GR	A2-0120 694	(10/84)	EP	—	—	
AN GR	WO92/11018	(07/92)	WO	—	—	
AO GR	WO93/02191	(02/93)	WO	—	—	
AP GR	A1-0368 684	(05/90)	EP	—	—	
AQ GR	WO94/11509	(05/94)	WO	—	—	
AR GR	A1-0519 596	(12/92)	EP	—	—	
AS GR	A1-0592 106	(04/94)	EP	—	—	
AT GR	A1-0125 023	(11/84)	EP	—	—	
AU GR	A2-0239 400	(09/87)	EP	—	—	
AV GR	B1-0239 400	(09/87)	EP	—	—	
AW GR	A2-0188 941	(10/87)	GB	—	—	
AX GR	WO88/09344	(12/88)	WO	—	—	
AY GR	A1 0318 554	(06/89)	EP	—	—	
AZ GR	WO89/01783	(03/89)	WO	—	—	
A1 GR	A1-0323 806	(07/89)	EP	—	—	
A2 GR	A 0328 404	(08/89)	EP	—	—	
A3 GR	WO89/09622	(10/89)	WO	—	—	
A4 GR	A2 0365 209	(04/90)	EP	—	—	
A5 GR	A2 0365 997	(05/90)	EP	—	—	

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

D1 GR	Wu and Kabat, J. Exp. Med., 132 (1970) 211-250
D2 GR	Palm, Hoppe-Seyler's Z. Physio Chem. 354 (1973), 1651-1654 Abstract only
D3 GR	Epp., Eur. J. Biochem. 45 (1974), 513-524
D4 GR	Palm, Hoppe-Seyler's Z. Physio. Chem. 356 (1975), 167-191 Abstract only

Julie Crews RD

13 JA 99

FORM PTO-1449 (Modified)		Attorney Docket No. 011823-002630	Serial No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen	
		Filing Date: 6/7/95	Group: 1806
D62	QR	Kabat, Sequences of Proteins of Immunological Interest, US Dept. of Health and Human Services, 1991 Edition <i>pages vii -o XXvii</i>	
D63	QR	Co, J. Immunol., 148, (1992), 1149-1154	
D64	QR	Foote, J. Mol. Biol., 224, (1992), 487-499	
D65	QR	Carter, Proc. Natl. Acad. Sci., USA, 89 (1992) 4285-4289	
D66		Queen Application (Protein Design Laboratories) See AN <i>See Foreign Patent Documents</i>	
D67		Waldmann Application (Wellcome Foundation) See AO <i>" " " "</i>	
D68	QR	Tempest, Hybridoma, 13 (1994), 183-190	
D69	QR	Corti, J. Mol. Biol., 235 (1994), 53-60	
D70	QR	Adair, Hum. Antibod. Hybridomas, 5, (1994), 41-47	
D71	QR	Padlan, Molecular Immunol., 31 (1994), 169-217	
D72	QR	Ellis, J. Immunol., 155 (1995), 925-937	
D73	QR	Tempest, Int. J. Biol. Macromol., 17 (1995), 37-42	
D74	QR	Ohtomo, Molecular Immunology, 32 (1995), 407-416	
D75	QR	Co, Cancer Res., 56 (1996), 1118-1125	
D76	QR	Rosen, Dictionary of Immunology, 12, 50, 99, 100	
D77	QR	Verhoeven D1.3 slide	
D78	QR	Pages 6 to 8 of USSN 07/310,252 (priority document claimed by the Opposed Patent)	
D79	QR	Alignment of rat YTH 34.5, human REI and humanized HUVLCAMP VL sequences from D1	
D80		EP 0 093 619, Decision of November 8, 1995	
D81	QR	Declaration of Dr. Winter (O I)	
D82	QR	Declaration of Dr. Tempest (O II)	
D83	QR	Declaration of Dr. Riechmann (O VIII)	
D84	QR	Declaration of Dr. Chothia (O III)	
D85	QR	Declaration of Dr. Padlan (O IX)	
D86	QR	Declaration of Dr. Rees (O XI)	
D87	QR	Biotech Experimental Report (O X)	
D88	QR	Comparison chart of light chain sequences described in Riechmann (D36)	
D89	QR	Rodrigues, Int. J. Cancer: Supplement 7 (1992) 45-50	
D90	QR	Sha, Cancer Biotherapy, 9 (1994), 341-349	
D91		Winter (Medical Research Council) See AP <i>See Foreign Patent Documents</i>	

Julie Rees PLO

13 Jan 99

FORM PTO-1449 (Modified)		Attorney Docket No. 011823-002630	Serial No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Queen	
		Filing Date: 6/7/95	Group: 1806
D92 <i>QR</i>	Couto, Hybridoma, 13 (1994), 215-219		
D93	Couto (Cancer Research Fund of Contra Costa) See AQ <i>See Foreign Patent Document</i>		
D94	Padlan Application (Merck & Co., Inc./NIH) See AR <i>See Foreign Patent Document</i>		
D95	Pedersen Application (Immunogen) See AS <i>" " " "</i>		
D96 <i>QR</i>	Couto, Cancer Research, Supplement 55, (1995), 1717-1722		
D97 <i>QR</i>	Nakatani, Protein Engineering, 7, (1994), 435-443)		
D98 <i>QR</i>	Presta, Cancer Research, 57, (1997), 4593-4599		
D99 <i>QR</i>	Hieter, J. Biol. Chem., 257, (1982), 1516-1522		
D100 <i>QR</i>	"Polygen Corporation" in New Products, Chemical Design Corporation, Automation, 3(11), November 1988		
D101 <i>QR</i>	"Biosym Technologies" in New Products, Chemical Design Automation, 3(4), December 1988		
D102 <i>QR</i>	Vicenti, New Engl. J. Med., 338 (1998), 161-165		
EXAMINER	<i>Shaw, PLD</i>	DATE CONSIDERED	<i>13 Jan 99</i>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.